Author:
de Villemeur T. Billette,Deslys J-P.,Pradel A.,Soubrie C.,Alperovitch A.,Tardieu M.,Chaussain J-L.,Hauw J-J.,Dormont D.,Ruberg M.,Agid Y.
Abstract
We diagnosed Creutzfeldt-Jakob disease in 34 patients (16 definite, 18 probable) who had received human growth hormone extract for various periods of time (mean +/- SD, 6.4 +/- 2.9 years), but particularly during the period between January 1984 and July 1985, a potential high-risk factor. Disease duration for deceased patients (n = 30) was 17 +/- 9 months. The clinical picture was homogeneous, starting with cerebellar ataxia and ocular motor disorders in about 90% of the patients. Neurologic deterioration, including dementia and myoclonic jerks, occurred within months. The high number of cases (1.5% of those treated between 1959 and 1988, 3% of those treated during the putative high-risk period) is still unexplained. We discuss the possibility that new cases will be detected, the risk of contaminating the general public, and the sanitary measures undertaken to prevent this.NEUROLOGY 1996;47: 690-695
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Les maladies à prions ou encéphalopathies spongiformes transmissibles;La Revue de Médecine Interne;2022-02
2. Creutzfeldt-Jakob Disease;Research Anthology on Diagnosing and Treating Neurocognitive Disorders;2021
3. An astrocyte cell line that differentially propagates murine prions;Journal of Biological Chemistry;2020-08
4. Human Pituitary Hormones and Creutzfeldt-Jakob Disease;Encyclopedia of Reproductive Technologies;2019-08-19
5. Prion Diseases: A Concern for Mankind;Pathogenicity and Drug Resistance of Human Pathogens;2019